Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1954 1
1964 1
1966 1
1967 2
1968 4
1970 1
1971 2
1972 3
1973 1
1974 5
1975 5
1976 9
1977 15
1978 13
1979 13
1980 10
1981 8
1982 14
1983 12
1984 18
1985 12
1986 13
1987 14
1988 18
1989 18
1990 22
1991 16
1992 20
1993 15
1994 20
1995 23
1996 27
1997 38
1998 27
1999 24
2000 20
2001 23
2002 33
2003 38
2004 29
2005 58
2006 55
2007 51
2008 50
2009 54
2010 53
2011 69
2012 83
2013 86
2014 104
2015 106
2016 123
2017 141
2018 128
2019 118
2020 137
2021 121
2022 119
2023 103
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

2,105 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
Furthermore, approximately 15% of patients with ET or PV might progress into a PMF-like phenotype (post-ET/PV MF) during their clinical course. ADVERSE MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF, independent of each other and …
Furthermore, approximately 15% of patients with ET or PV might progress into a PMF-like phenotype (post-ET/PV MF) during their clinical c …
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. Harrison C, et al. N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. N Engl J Med. 2012. PMID: 22375970 Free article. Clinical Trial.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Passamonti F, et al. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. Leukemia. 2017. PMID: 28561069
No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. ...Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) allo …
No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we …
Management of Myelofibrosis-Related Cytopenias.
Bose P, Verstovsek S. Bose P, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Curr Hematol Malig Rep. 2018. PMID: 29796726 Review.
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H; COMFORT-I investigators. Verstovsek S, et al. J Hematol Oncol. 2017 Feb 22;10(1):55. doi: 10.1186/s13045-017-0417-z. J Hematol Oncol. 2017. PMID: 28228106 Free PMC article. Clinical Trial.
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. Cervantes F, et al. Blood. 2009 Mar 26;113(13):2895-901. doi: 10.1182/blood-2008-07-170449. Epub 2008 Nov 6. Blood. 2009. PMID: 18988864 Free article.
To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 centers were studied. ...Compared with prior prognostic models, the new risk stratification system displayed higher predictive …
To enhance this process by developing a highly discriminative prognostic system, 1054 patients consecutively diagnosed with PMF at 7 …
Essential thrombocythemia.
Brière JB. Brière JB. Orphanet J Rare Dis. 2007 Jan 8;2:3. doi: 10.1186/1750-1172-2-3. Orphanet J Rare Dis. 2007. PMID: 17210076 Free PMC article. Review.
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Kiladjian JJ, et al. Lancet Haematol. 2020 Mar;7(3):e226-e237. doi: 10.1016/S2352-3026(19)30207-8. Epub 2020 Jan 23. Lancet Haematol. 2020. PMID: 31982039 Free PMC article. Clinical Trial.
Alleviating anemia and thrombocytopenia in myelofibrosis patients.
Cervantes F, Correa JG, Hernandez-Boluda JC. Cervantes F, et al. Expert Rev Hematol. 2016 May;9(5):489-96. doi: 10.1586/17474086.2016.1154452. Epub 2016 Mar 2. Expert Rev Hematol. 2016. PMID: 26891375 Review.
Anemia and thrombocytopenia are frequent clinical manifestations of myelofibrosis as well as important prognostic factors of the disease. Concerning the treatment of anemia, the first step should be the correction of reversible contributing factors, such as possible iron, …
Anemia and thrombocytopenia are frequent clinical manifestations of myelofibrosis as well as important prognostic factors of the dise …
2,105 results